Latest Antiplatelet drug Stories

Studies conducted on the blood-thinning drug Plavix indicate no benefit when taken with aspirin and may increase changes of suffering a stroke. The Law Firm of d'Oliveira & Associates wishes to inform the general public that with Plavix going generic, cases of side effects associated with the drug may increase. (PRWEB) May 06, 2013 Marketed by Bristol-Myers Squibb and Sanofi Pharmaceuticals and currently the second most commonly prescribed drug on the U.S. market, Plavix is used...

RIDGEFIELD, Conn., April 30, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced three important updates to the U.S. prescribing information for PRADAXA, an oral anticoagulant (OAC) indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). The PRADAXA label now carries a Boxed Warning, similar to the Boxed Warnings in the labels of other new OACs, to advise patients that discontinuing treatment...

redOrbit Staff & Wire Reports - Your Universe Online Using aspirin for cardiovascular health remains a popular preventative medicine regimen for many people, even though recent studies have suggested that the popular pain killer might not be as beneficial as previously believed, according to new research published in the journal Canadian Family Physician. Study authors Olga Szafran and Mike Kolber of the University of Alberta’s Department of Family Medicine polled patients over...

Rate of brain hemorrhage in stroke patients given tPA isn't meaningfully higher Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots. But when one of them suffers a stroke caused by a clot in their brain, some emergency teams might hesitate to give a powerful clot-busting medication called tPA -- for fear that the combination of drugs might cause dangerous brain bleeding. Now, a University of...

ReportsnReports.com adds new market research report “Research Report on China's Antithrombotic Drug Market, 2013-2017” to its store. Dallas, Texas (PRWEB) January 03, 2013 Thrombosis refers to the formation of local blood clots. Among it, artery thrombosis can cause myocardial infarction, stroke, acute coronary syndrome, peripheral arterial diseases, etc.; venous thrombosis can cause pulmonary embolism. Arteriovenous thrombosis is the primary reason for incidence and death of...

University of Warwick Scientists may have discovered a new way to prevent strokes in high risk patients, according to research from the University of Warwick and University Hospitals Coventry and Warwickshire (UHCW). Work by a new research group, led by Professor Donald Singer, Professor of Therapeutics at Warwick Medical School and Professor Chris Imray from UHCW, has now been published in US journal Stroke. The group is using ultrasound scanning to look at patients with carotid...

DALLAS, November 20, 2012 /PRNewswire/ -- - RnRMarketResearch.com adds new market research reports "Antithrombotic / Anticoagulant Drugs: Technologies and Global Markets" to its store. This report provides an overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals. Analyses of global market trends, with data from 2011,...

BARCELONA, Spain, November 5, 2012 /PRNewswire/ -- Life Science Entrepreneurs S.L.U., a company dedicated to the early-stage development of high-risk/very high return ventures, announced today the conclusion of a first investment for an antiplatelet drug candidate code-named NmC. Private investors from Barcelona, Geneva and Basel, all active in medical applications of life sciences, have funded the assays to confirm the safety and efficacy of the cardiovascular drug...

BOSTON, Oct. 13, 2012 /PRNewswire/ -- The pros and cons of newer versus older antiplatelet agents in patients with diabetes, the utility of genetic and platelet function testing, and the value of triple combination antiplatelet therapy will be debated by experts at a perennial favorite Cardiometabolic Health Congress (CMHC) session today. The "Hot Topics in Thrombosis and ACS" session is moderated by Deepak L. Bhatt, MD, MPH, professor of medicine at Harvard Medical School, chief of...

The findings were presented by Dr Jolanta Siller-Matula from Medical University of Vienna Standard antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) consists of a dual antiplatelet therapy with aspirin and an ADP receptor inhibitor such as clopidogrel. But measurements of platelet aggregation in clopidogrel treated patients indicate that one patient in four is a non-responder to the drug. Such non-responsiveness is attributed to clopidogrel's...